Data as of Jan 23
| -0.37 / -0.84%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk have a median target of 48.32, with a high estimate of 58.18 and a low estimate of 35.65. The median estimate represents a +10.12% increase from the last price of 43.88.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.